Molecular Testing in the Management of Pulmonary Nodules
Customize your policy alerts
Sign up for Blue Cross Blue Shield - Massachusetts Policy 029 alerts
Get alerted when Policy 029 changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage and prior authorization for plasma-based proteomic screening and related molecular testing used to risk-stratify undiagnosed pulmonary nodules detected by computed tomography for applicable commercial and Medicare Advantage members.
The policy statement and evidence review for the Percepta Genomic Sequencing Classifier were removed because the product is no longer marketed.
The REVEAL Lung Nodule Characterization test by MagArray was removed from the policy statements because the company is no longer in business.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.